Shopping Cart

Your shopping cart is currently empty

Tovinontrine

Name: Tovinontrine
Brand: TargetMol
SKU: T61833
Price: 64 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T61833Cas No. 2062661-53-2

Alias IMR-687

Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].

Tovinontrine

😃Good

Purity: 98.8%

Catalog No. T61833Alias IMR-687Cas No. 2062661-53-2

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$64	-	In Stock
5 mg	$158	-	In Stock
10 mg	$227	-	In Stock
25 mg	$367	-	In Stock
1 mL x 10 mM (in DMSO)	$173	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.8%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].
Targets&IC50	PDE5A2:81.9 μM, PDE1B:8.48 μM, PDE1A3:88.4 μM, PDE9A2:9.99 nM, PDE9A1:8.19 nM, PDE1C:12.2 μM
In vitro	Tovinontrine (IMR-687) (0.03-10 μM) treatment for 6 hours in erythroid K562 cells increases cGMP in a dose-dependent manner.[1] IMR-687 (0.1-10 μM) treatment in erythroid K562 cells for 72 hours induces hemoglobin (HbF) in a dose-dependent manner.[1]
In vivo	Tovinontrine (IMR-687) (30 mg/kg/day; 30 days) resulted in a more than three-fold increase in the proportion of HbF+ F-cells (8.4% in the vehicle-treated group and 27.3% in the IMR-687 treated group), accompanied by a corresponding two-fold reduction in sickled red blood cells (56.3% in the vehicle-treated group and 24.4% in the IMR-687 treated group).[1]
Synonyms	IMR-687

Chemical Properties

Molecular Weight	394.47
Formula	C₂₁H₂₆N₆O₂
Cas No.	2062661-53-2
Smiles	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(ncc2c(=O)[nH]1)C1CCOCC1

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 90 mg/mL (228.15 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.37 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5350 mL	12.6752 mL	25.3505 mL	126.7524 mL
5 mM	0.5070 mL	2.5350 mL	5.0701 mL	25.3505 mL
10 mM	0.2535 mL	1.2675 mL	2.5350 mL	12.6752 mL
20 mM	0.1268 mL	0.6338 mL	1.2675 mL	6.3376 mL
50 mM	0.0507 mL	0.2535 mL	0.5070 mL	2.5350 mL
100 mM	0.0254 mL	0.1268 mL	0.2535 mL	1.2675 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc